-
Something wrong with this record ?
Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis
Q. Tang, D. Ramsköld, O. Krystufkova, HF. Mann, C. Wick, M. Dastmalchi, T. Lakshmikanth, Y. Chen, J. Mikes, H. Alexanderson, A. Achour, P. Brodin, J. Vencovsky, IE. Lundberg, V. Malmström,
Language English Country England, Great Britain
Document type Journal Article, Randomized Controlled Trial
NLK
Free Medical Journals
from 1997 to 1 year ago
Medline Complete (EBSCOhost)
from 1972-01-01 to 1 year ago
Wiley Free Content
from 1997 to 1 year ago
PubMed
30451307
DOI
10.1111/sji.12732
Knihovny.cz E-resources
- MeSH
- Abatacept therapeutic use MeSH
- Dermatomyositis blood drug therapy immunology MeSH
- Adult MeSH
- Immunosuppressive Agents therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- B-Lymphocyte Subsets drug effects MeSH
- Polymyositis blood drug therapy immunology MeSH
- T-Lymphocyte Subsets drug effects MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Randomized Controlled Trial MeSH
We aimed to evaluate in vivo effects of abatacept on phenotypes of T and B cells in the circulation of myositis patients in a sub-study of the ARTEMIS trial. Twelve patients with paired frozen PBMCs before and after 6-month abatacept treatment were included in this sub-study where mass cytometry (CyTOF) was chosen as a technology to be tested for its utility in a real-life clinical immune monitoring setting. Using CyTOF, the peripheral T cell phenotypes demonstrated considerable variation over time and between individuals precluding the identification of treatment-specific changes. We therefore conclude that studies of patient cohorts displaying wide clinical heterogeneity using mass cytometry must be relatively large in order to be suited for discovery research and immune monitoring. Still, we did find some correlations with functional muscle outcome, namely positive correlations between the ratio of CD4+ T cells and CD8+ T cells (CD4/CD8) in peripheral blood samples both at baseline and after treatment with muscle endurance improvement as assessed by the functional index-2 (FI-2) test. Our data suggest that the CD4/CD8 ratio in circulation at time of active disease may be a predictor of treatment efficacy in myositis patients.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19012138
- 003
- CZ-PrNML
- 005
- 20190416083934.0
- 007
- ta
- 008
- 190405s2019 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/sji.12732 $2 doi
- 035 __
- $a (PubMed)30451307
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Tang, Quan $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
- 245 10
- $a Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis / $c Q. Tang, D. Ramsköld, O. Krystufkova, HF. Mann, C. Wick, M. Dastmalchi, T. Lakshmikanth, Y. Chen, J. Mikes, H. Alexanderson, A. Achour, P. Brodin, J. Vencovsky, IE. Lundberg, V. Malmström,
- 520 9_
- $a We aimed to evaluate in vivo effects of abatacept on phenotypes of T and B cells in the circulation of myositis patients in a sub-study of the ARTEMIS trial. Twelve patients with paired frozen PBMCs before and after 6-month abatacept treatment were included in this sub-study where mass cytometry (CyTOF) was chosen as a technology to be tested for its utility in a real-life clinical immune monitoring setting. Using CyTOF, the peripheral T cell phenotypes demonstrated considerable variation over time and between individuals precluding the identification of treatment-specific changes. We therefore conclude that studies of patient cohorts displaying wide clinical heterogeneity using mass cytometry must be relatively large in order to be suited for discovery research and immune monitoring. Still, we did find some correlations with functional muscle outcome, namely positive correlations between the ratio of CD4+ T cells and CD8+ T cells (CD4/CD8) in peripheral blood samples both at baseline and after treatment with muscle endurance improvement as assessed by the functional index-2 (FI-2) test. Our data suggest that the CD4/CD8 ratio in circulation at time of active disease may be a predictor of treatment efficacy in myositis patients.
- 650 _2
- $a abatacept $x terapeutické užití $7 D000069594
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a podskupiny B-lymfocytů $x účinky léků $7 D016175
- 650 _2
- $a dermatomyozitida $x krev $x farmakoterapie $x imunologie $7 D003882
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunosupresiva $x terapeutické užití $7 D007166
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a polymyozitida $x krev $x farmakoterapie $x imunologie $7 D017285
- 650 _2
- $a T-lymfocyty - podskupiny $x účinky léků $7 D016176
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Ramsköld, Daniel $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Krystufkova, Olga $u Institute of Rheumatology Prague, Prague, Czech Republic.
- 700 1_
- $a Mann, Herman F $u Institute of Rheumatology Prague, Prague, Czech Republic.
- 700 1_
- $a Wick, Cecilia $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Dastmalchi, Maryam $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Lakshmikanth, Tadepally $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Chen, Yang $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Mikes, Jaromir $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Alexanderson, Helene $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden. Functional Area Occupational Therapy and Physical Therapy, Karolinska University Hospital, and Division of Physiotherapy, Department of NVS, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Achour, Adnane $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Brodin, Petter $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. Department of Neonatology, Karolinska University Hospital, Stockholm, Sweden.
- 700 1_
- $a Vencovsky, Jiri $u Institute of Rheumatology Prague, Prague, Czech Republic.
- 700 1_
- $a Lundberg, Ingrid E $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
- 700 1_
- $a Malmström, Vivianne $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
- 773 0_
- $w MED00010600 $t Scandinavian journal of immunology $x 1365-3083 $g Roč. 89, č. 1 (2019), s. e12732
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30451307 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190416083959 $b ABA008
- 999 __
- $a ok $b bmc $g 1391448 $s 1050443
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 89 $c 1 $d e12732 $e 20181209 $i 1365-3083 $m Scandinavian journal of immunology $n Scand J Immunol $x MED00010600
- LZP __
- $a Pubmed-20190405
